GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AROANG-3 overview

AROANG-3 is under development for the treatment of dyslipidemic patients including familial hypercholesterolemia including homozygous familial hypercholesterolemia and heterozygous familial hypercholesterolemia (heFH), severe hypertriglyceridemia and mixed dyslipidemia. It is administered through subcutaneous route. The therapeutic candidate is a siRNA acts by targeting angiopoietin-like 3 protein (ANGPTL3). The drug candidate is developed based on targeted RNAi molecule (TRiM) platform.

Arrowhead Pharmaceuticals overview

Arrowhead Pharmaceuticals (Arrowhead), formerly Arrowhead Research, is a pharmaceutical company. It develops and markets medicinal products including ARO-AAT, JNJ-3989, ARO-APOC3, ARO-ANG3, ARO-ENaC, ARO-HIF2, ARO-Lung2, ARO-HSD, ARO-HIF2, AMG 890, ARO-JNJ1, ARO-JNJ2 and ARO-JNJ3.The company develops pipeline drugs that are being developed to treat chronic hepatitis B infection for the treatment of liver disease, cardiovascular disease, hypertriglyceridemia, dyslipidemia, cystic fibrosis and and renal cell carcinoma. It also offers design of internal preclinical and clinical development programs to enable novel new therapies. The company has operations in California and Wisconsin, the US. Arrowhead is headquartered in Pasadena, California, the US.

For a complete picture of AROANG-3’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.